TFE3 and kidney cancer: Our work illuminates actionable metabolic features driven by the TFE3 fusion in tRCC that are distinct from other RCC subtypes, offering hope that molecularly-directed therapies can be advanced to specifically target the biology of this aggressive subtype of kidney cancer.